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AbstrACt
Objective The aim of this study was to examine the 
association between musculoskeletal (MSK) pain, 
insomnia, anxiety and depressive symptoms in patients 
from general practice.
Design This is a cross-sectional study.
setting This study was conducted in general practice in 
Denmark.
Participants A consecutive sample of 390 general 
practice patients (aged 12 years or older) were included; 
183 patients with MSK pain and 207 patients without MSK 
pain. To be included in the MSK pain group, participants 
with MSK pain were required to report MSK pain at least 
weekly during the preceding month, which had a negative 
impact on daily activities.
Primary and secondary outcomes measures The 
primary outcome was insomnia evaluated by the 
Athens Insomnia Scale. The secondary outcomes were 
psychological symptoms assessed by the Hospital Anxiety 
and Depression Scale.
results Patients with MSK pain had a significantly higher 
prevalence of insomnia (difference 25.5%, p<0.0001), 
anxiety (difference 24.3%, p<0.0001) and depressive 
symptoms (difference 11%, p<0.0001) compared with 
patients without MSK pain. Furthermore, patients with 
MSK pain and comorbid insomnia had significantly higher 
levels of anxiety and symptoms of depression compared 
with patients with MSK pain without insomnia (p<0.0001). 
These relationships remained robust when controlling for 
age, sex and body mass index in linear regression.
Conclusion One in two patients in general practice report 
MSK pain. Comorbid MSK pain and insomnia are common 
and are associated with a higher prevalence of anxiety and 
depression. This highlights the importance of establishing 
the presence of insomnia and affective disorders as 
potentially modifiable factors during treatment of MSK pain 
in general practice.
IntrODuCtIOn
Chronic pain is a global public health concern 
posing a burden to both the individual and 
the society.1 Of all chronic pain complaints, 
musculoskeletal (MSK) pain is the most 
common, and the most frequent reason for 
long-term illness and sick leave in Denmark.2 
In general practice, MSK pain forms the 
largest diagnostic group, accounting for 14% 
of all consultations and two-thirds of painful 
conditions.3 MSK pain has a large impact as 
it affects activities of daily living, and patients 
report lower quality of life compared with 
pain-free individuals.4 
Insomnia is a similarly common problem in 
general practice, affecting 10% of patients.5 
Perhaps unsurprisingly, there is a clear asso-
ciation between MSK pain and sleep distur-
bances.6 Patients with MSK pain suffer more 
from insomnia, and insomnia may be an inde-
pendent risk factor for developing pain, and 
is associated with worse prognosis in those 
with MSK pain.7
Psychological factors (such as depression 
and anxiety) are other important factors 
strength and limitations of this study
 ► The study was rigorously designed using predefined 
hypotheses, methods and outcomes that were pilot 
tested to ensure comprehensibility.
 ► We used previously validated and reliable ques-
tionnaires to assess insomnia and psychological 
symptoms.
 ► The limitation of the study is the cross-sectional 
study design, meaning we cannot make any infer-
ences regarding causality between the parameters 
assessed. Further longitudinal research is therefore 
needed to outline the mechanisms, which link the 
three parameters.
 ► The self-report nature of the study could lead to an 
overestimation of some of the problems, for exam-
ple, the number of patients with clinical anxiety or 
the number of patients using pain-relieving drugs.
copyright.
 on O
ctober 14, 2019 at A
alborg U
niversity Library. P
rotected by
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2019-031971 on 29 June 2019. D
ow
nloaded from
 
2 Sørensen L, et al. BMJ Open 2019;9:e031971. doi:10.1136/bmjopen-2019-031971
Open access 
associated with increased pain and worse prognosis.8 Pain 
may also result in new onset of psychological disorders, 
suggesting a bidirectional relationship between the two.1 9 
Furthermore, these factors may be related to insomnia 
as there has been a connection between both pain and 
affective disorders and between affective disorders and 
insomnia.10 Preliminary research from secondary care has 
found links between chronic pain, mood disorders and 
insomnia, suggesting a potential association between the 
three.11–13 This is potentially linked to the stress response 
which is implicated in patients with MSK pain with both 
mood and sleep disorders.10
However, it is unclear whether similar observations 
can be found in patients with MSK pain in primary care, 
where most MSK problems are identified and managed. 
Despite the potential interacting and reciprocal rela-
tionships between MSK pain, insomnia and psycholog-
ical symptoms, there is a lack of research examining all 
three factors in primary care patients with MSK pain. It 
remains to be answered if those patients in primary care 
with comorbid MSK pain and insomnia also have an 
increased prevalence of psychological symptoms. Given 
the significant impact of sleep disturbance and affective 
disorders on MSK pain and the fact that MSK pain is a 
frequent reason for primary care consultations, the focus 
of this study was to explore the prevalence, characteris-
tics and links between MSK pain, insomnia, and depres-
sive and anxiety symptoms in primary care patients. This 
can potentially inform primary care strategies to provide 
evidence-based multifaceted anticipatory and preventive 
care for patients with MSK complaints.
The primary aim of this study was to investigate the 
prevalence of insomnia among patients in general prac-
tice with MSK pain compared with control patients in 
general practice without MSK pain. The hypothesis was 
that a higher proportion of patients with MSK pain would 
be classified as ‘insomniacs’ compared with the control 
group.
The secondary aim was to explore whether psycho-
logical symptoms (depression and anxiety) were higher 
among patients with MSK pain with concurrent insomnia. 
The hypothesis was that patients with comorbid MSK 
pain and insomnia have more psychological symptoms 
compared with patients with MSK pain alone.
Finally, within the MSK pain group, we aimed to inves-
tigate if the prevalence of insomnia and psychological 
symptoms were more common in patients with wide-
spread MSK pain compared with those with localised 
pain.
MethODs
study design and setting
This study is designed a cross-sectional question-
naire-based study, conducted between the 6th–23 
rd November 2017 in a general practice in Nors, Northern 
Jutland, Denmark. The general practice has a patient 
population of 5938 patients (November 2017). The 
reporting of the manuscript follows Strengthening the 
Reporting of Observational Studies in Epidemiology 
guidelines. Prior to conducting the study, a full study 
protocol was written, in which the outcomes, hypotheses 
and analyses were predefined (available as online supple-
mentary appendix).
Patient and public involvement
Patients were not involved with the design of this study.
Participants
Patients aged 12 years or older consulting the practice 
during the study period were asked to complete the ques-
tionnaire by doctors, nurses or the medical laboratory 
technician. The participants were not given any informa-
tion of the content of the questionnaire beforehand, thus 
reducing the risk of selection bias.
Measures
The self-report questionnaire was based on existing and 
validated surveys, and consisted of demographic param-
eters, self-reported MSK pain, insomnia, anxiety and 
depressive symptoms (outlined below). Prior to data 
collection, the questionnaire was piloted in the clinic on 
18 patients and adolescents aged 12–14 years to ensure 
comprehensibility. The same questionnaire was handed 
out to children and adults.
Musculoskeletal Pain
A structured pain questionnaire was designed to assess 
different aspects of MSK pain. Patients were asked if they 
had experienced pain at least weekly during the preceding 
month, and if so, to mark the exact location of their 
pain on an outlined manikin of the human body. Those 
reporting pain were subsequently asked to report pain 
frequency (rarely, monthly, once a week, more than once a week, 
almost daily), pain duration and pain intensity (measured 
as average and worst pain during the preceding week on 
numeric rating scale ranging from 0 to 10 ranging from 
no pain to worst imaginable pain). Patients were asked to 
indicate if they had consulted their general practitioner 
for their pain, and if the cause of pain was known (eg, a 
specific diagnosis such as osteoarthritis). They were also 
asked if pain had a negative influence on their daily activ-
ities (none, little, moderate, large or cannot perform due to pain) 
and whether they took any pain-relieving medication.
Participants were eligible for inclusion in the MSK pain 
group if they met the following criteria:
1. MSK pain at least once a week during the preceding 
month.
2. This pain negatively interfered with their usual 
activities.
Participants were categorised as having widespread 
pain (WSP) if they fulfilled the criteria from The Amer-
ican College of Rheumatology: pain in both the left and 
the right sides of the body, pain above and below the 
waist, and pain in the axial skeleton.14
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sleep
The primary outcome was the Athens Insomnia Scale 
(AIS-8).15 It consists of eight items scored on Likert-
type scales ranging from 0 (no problem at all) to 3 (very 
severe sleep problem). The patients rated the item posi-
tive if it occurred at least three times per week during 
the last month. The internal consistency and external 
validity of the AIS-8 are high (Cronbach’s alpha=0.89 and 
Pearson’s correlation coefficient with the Sleep Prob-
lems Scale=0.90, respectively) and it has established test–
retest reliability (0.89).15
The sleep questionnaire was translated using the dual-
panel translation method (translation and use of the 
AIS-8 by permission of Professor C. R. Soldatos, author of 
AIS-8).15 The cut-off score for classifying insomnia is 6.16
Psychological symptoms
Psychological symptoms were anxiety and depressive 
symptoms, assessed by the Hospital Anxiety and Depres-
sion Scale (HADS). HADS is a 14-item self-report ques-
tionnaire, which consists of an anxiety (HADS-A) and 
a depression subscale (HADS-D). Responses are scored 
from 0 to 3 (each subscale ranges from 0 to 21).
Cronbach’s alpha is 0.83 for HADS-A and 0.82 for 
HADS-D, and the validity of HADS is good to very good 
(correlation 0.60–0.80) compared with Beck’s Depression 
Inventory.17 HADS has previously been translated into 
Danish using the forward-backward translation method, 
and the translated version has been cross-culturally 
validated.18
statistical methods
Sample size calculation
Based on data from Paparrigopoulos et al,19 the propor-
tion of participants with chronic disease with insomnia 
(according to the AIS-8) was 42.8%, compared with 15.5% 
of controls. We estimated that 20% of the patients in our 
control group would be classified as having insomnia (as 
our sample was general practice patients, and some may 
suffer from chronic diseases), and 35% of the patients 
from our MSK pain group would be classified as having 
insomnia. Using a p value of 0.05 and power of 80%, the 
ratio between the sample sizes was set at 0.14 (as MSK 
pain accounts for 14% of all general practice consulta-
tions3). This gave us a final sample size of 73 patients with 
MSK pain, from an estimated total of 598 patients.
Statistical analyses
All data from the questionnaires were entered electroni-
cally and subsequently rechecked for typing errors by one 
person. Missing data in HADS were managed using the 
‘half rule’ method, meaning that the patient’s subscale 
mean (for the HADS-A and HADS-D, respectively) was 
used to fill in the missing data, given that at least half 
of the subscale was answered; otherwise, the patient was 
excluded.20 The same method was used for the AIS-8. 
Patients were excluded from the study if they had failed 
to answer the questions, which allocated them to either 
the MSK pain group or the control group.
χ2 test of independence was used for the primary anal-
ysis to determine differences in proportions of those 
categorised as ‘insomniacs’ in the MSK pain group versus 
control group. Unpaired t-tests were used to analyse 
continuous scores from HADS, if normally distributed 
(checked by visual assessment of Q–Q plots), to detect 
differences in anxiety and depressive symptoms between 
the MSK pain group versus control group and reported 
using mean values and effect sizes. Unpaired t-tests 
were used to determine differences between subgroups 
(patients with MSK pain alone vs patients with MSK pain 
and comorbid insomnia, and patients with localised MSK 
pain vs WSP).
χ2 test of independence was applied to detect differ-
ences in proportion of insomniacs (categorised according 
to the AIS-8 cut score of 6) between patients with local-
ised pain versus WSP. For all analyses, the level of statis-
tical significance was set at p<0.05. Data were analysed 
using the SPSS software (Version 22.0).
Post hoc regression analyses
Based on peer review comments, post hoc regression anal-
yses were run to ensure the reported relationships were 
not an artefact due to differences in age, sex and body 
mass index (BMI). For the primary outcome (sleep prob-
lems measured on the AIS-8 as a continuous variable), 
hierarchical linear regression was conducted to test the 
added predictive value of MSK pain (pain at least once 
a week during the preceding month and this pain nega-
tively interfered with usual activities) in predicting sleep 
problems when adjusting for age, BMI and sex (male vs 
female). Therefore, block 1 included the age, sex and 
BMI, and block 2 included MSK pain as a dichotomous 
predictor variable.
This was also done for the secondary outcomes depres-
sion (HADS-D) and separately anxiety (HADS-A). For the 
secondary outcomes, age, sex and BMI were included in 
block 1 to evaluate the additional predictive capacity of 
MSK pain in block 2, and insomnia (as a binary predictor 
variable based on AIS cut score) in block 3.
results
A total of 424 patients out of 977 eligible patients (43.4%) 
participated in the study. Of the subjects who responded, 
34 were excluded due to incomplete data (in either the 
AIS-8, HADS or the pain questionnaire). Consequently, 
390 patients were included in the study, of which 183 
(46.9 %) were categorised as patients with MSK pain 
(mean age 54.2±18.5 years) and 207 (53.1%) controls 
(mean age 53.7±21.0 years).
Demographic characteristics are presented in table 1. 
Of those with MSK pain, 71% had daily pain and 58% had 
contacted their general practitioner (GP) for their pain 
complaint (table 2).
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Prevalence of insomnia
A significantly greater proportion of the MSK pain group 
had insomnia compared with the control group (65.6% 
vs 40.1%; mean difference 25.5 (95% CI 15.6 to 34.6); 
χ2=25.26; p<0.0001; table 3).
Anxiety and depressive symptoms
The MSK pain group had significantly higher levels of 
anxiety as illustrated by higher HADS-A score compared 
with the control group (mean difference 2.6 (95% CI 
1.8 to 3.4); t-value=6.718; p<0.0001; table 3). Similarly, 
HADS-D was significantly higher in the MSK pain group 
compared with the controls (mean difference 1.6 (95% 
CI 1.0 to 2.2); t-value=5.346; p<0.0001; table 3).
subgroup comparisons
Patients with MSK pain and comorbid insomnia had 
significantly greater anxiety and depressive symptoms 
compared with patients with MSK pain and no insomnia 
(mean difference 4.1 (95% CI 2.9 to 5.2); t-value=6.871; 
p<0.0001 and mean difference 3.2 (95% CI 2.3 to 4.2); 
t-value=6.716; p<0.0001, respectively; table 4).
A significantly greater proportion of patients with WSP 
had insomnia (AIS-8 score ≥6) compared with patients with 
localised pain (78.0% vs 59.7%; difference in proportions 
18.3 (95% CI 3.7 to 30.7); p<0.05; table 5). Patients with 
WSP also had significantly more depressive symptoms 
compared with patients with localised MSK pain (mean 
difference 1.2 (95% CI 0.1 to 2.3); t-value=2.212; p<0.05; 
table 5). There were no statistical differences in anxiety 
(as measured by HADS-A) score between the two groups 
(mean difference (95% CI −0.7 to 1.9); t-value=0.893; 
p=0.373; table 5).
regression models adjusting for sex, age and bMI
For the outcome of sleep problems (AIS-8), the hierar-
chical linear regression was statistically significant, with 
the final model yielding an R2=0.191, F(4,360)=21.3; 
p<0.001. The addition of MSK pain to the model (block 
2) led to a statistically significant increase in R2=0.132, 
F(1,360) = 58.96; p<0.0001. See online supplementary file 
for full details.
For the secondary outcomes of depression and 
anxiety, the final models were statistically signifi-
cant (depression R2=0.388, F(5,359)=29.08; p<0.001) 
(anxiety R2=0.539, F(5,359)=29.45; p<0.001). The 
addition of MSK pain significantly improved the 
model compared with block 1 for depressive symp-
toms (R2 change=0.06; F(1,360)=24.52; p<0.001) and 
anxiety (R2 change=0.088, F(1,360)=37.15; p<0.001) 
subscales. The third block with the addition of insomnia 
significantly improved the model for depressive (R2 
change=0.168, F(1,359)=84.93; p<0.001) and anxiety 
(R2 change=0.144, F(1,359)=72.93; p<0.001) symptoms 
(see online supplementary file for full model details).
This underlines that MSK accounts for a significant 
proportion of the variance in predicting sleep problems, 
anxiety and depressive symptoms, and that insomnia has 
further predictive capacity of psychological symptoms, 
independent of MSK pain.
Table 1 Demographics
MSK pain group
Control 
group
Patients, n (%) 183 (46.9) 207 (53.1)
Sex, n (%)
  Male 63 (34.4) 93 (44.9)
  Female 120 (65.6) 114 (55.1)
Age in years, n (%)
  12–19 9 (4.9) 22 (10.8)
  20–29 15 (8.2) 18 (8.9)
  30–39 12 (6.6) 17 (8.4)
  40–49 31 (17.0) 20 (9.9)
  50–59 33 (18.1) 23 (11.3)
  60–69 41 (22.5) 44 (21.7)
  70–79 30 (16.5) 46 (22.7)
  80 and older 11 (6.0) 13 (6.4)
  BMI, mean (SD) 27.9 (5.9) 26.4 (5.0)
There are four missing values for age in the control group and one 
missing value in the musculoskeletal (MSK) pain group.
There are 16 missing values for body mass index (BMI) in 
the control group and 6 missing values in the MSK pain group.
Table 2 Pain characteristics (MSK pain group)
MSK pain 
group (n=183)
Pain frequency, n (%)
  Once a week 10 (5.5)
  Several times a week 43 (23.6)
  Almost daily 129 (70.9)
Average pain (numeric rating scale, mean 
(SD)
5.6 (1.7)
Duration of symptoms (months), median 
(IQR)
24 (9–85)
Use of pain-relieving drugs, n (%)
  Yes 133 (73.5)
  No 48 (26.5)
Contacts to GP for pain during the previous 6 months, n (%) 
  Several contacts 55 (30.1) 
  One contact 51 (27.9) 
  No contacts 77 (42.1) 
There is 1 missing value for pain frequency, 4 missing values for 
numeric rating scale, 45 missing values for duration of symptoms, 
2 missing values for use of pain-relieving drugs and 0 missing 
value for number of contacts to GP.
MSK, musculoskeletal.
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DIsCussIOn
Main findings
The findings of this study indicate that the typical patient 
in general practice with MSK pain commonly experiences 
co-occurring insomnia, anxiety and depressive symptoms. 
Regression analyses confirmed the independent associ-
ations, after adjusting for age, sex and BMI, with MSK 
contributing to an addition of 13.2% of the explain vari-
ance in sleep problems, 6.0% in depressive symptoms and 
8.8% in anxiety. Insomnia further significantly improved 
the prediction of psychological symptoms greater than 
MSK pain alone.
Importantly, patients who suffer from comorbid 
MSK pain and insomnia make up a high proportion of 
patients with MSK pain and will have more severe symp-
toms of depression and anxiety compared with those 
only suffering from MSK pain. Our results document 
a complex relationship between MSK pain, insomnia, 
anxiety and depression. These factors may depend on the 
extent of the pain, as those with WSP were more likely 
to experience insomnia and had more severe depressive 
symptoms. This highlights the importance of GPs to be 
cognisant to consider patients' pain complaints in the 
light of the biopsychosocial model. The high prevalence 
of both insomnia and WSP underscores the need for 
general practitioners to consider and enquire about these 
factors when treating patients with MSK pain in general 
practice.
Comparison with previous studies
The high prevalence of MSK pain and coexisting 
insomnia, depressive symptoms and anxiety in general 
practice may be partially attributable for MSK complaints 
being a leading cause for years lived with disability, glob-
ally.1 Our findings document a strong link between some 
of the conditions that account for the highest number of 
years lived with disability; MSK disorders and psycholog-
ical symptoms. These common conditions rarely exist in 
isolation. Our findings are in line with research in patients 
with chronic low back pain, documenting poorer self-re-
ported sleep, compared with individuals without pain,21 
and showing impaired sleep in patients when using objec-
tive measures of sleep.22
Table 3 Sleep and psychological characteristics
MSK pain group
(n=183)
Control group
(n=207)
Difference*
(95% CI)
Effect size
(Cohen's d) P value†
Sleep, n (%)
  Insomnia (AIS-8 score ≥6) 120 (65.6) 83 (40.1) 25.5 (15.6 to 34.6) N/A <0.0001
Sleep, mean (SD) 
  AIS-8 (0–24) 9.1 (5.7) 5.1 (4.1) 4.0 (3.0 to 5.0) 0.81 <0.0001
Anxiety and depression, n (%) 
  Anxiety (HADS-A ≥8) 71 (38.8) 30 (14.5) 24.3 (15.6 to 32.6) <0.0001
  Depression (HADS-D ≥8) 28 (15.3) 9 (4.3) 11.0 (5.1 to 17.2) N/A <0.0001
Anxiety and depression, mean (SD)
  HADS-A (0–21) 6.5 (4.3) 3.9 (3.4) 2.6 (1.8 to 3.4) 0.67 <0.0001
  HADS-D (0–21) 3.9 (3.5) 2.3 (2.4) 1.6 (1.0 to 2.2) 0.53 <0.0001
*Indicates difference in proportions with 95% CI for categorical variables and mean difference with 95% CI for continuous data, respectively.
†Statistically significant values are highlighted in bold. Unpaired t-tests were used to determine p values for continuous data, whereas χ2 tests 
were used to determine p values for difference in proportions (categorical variables).
AIS-8, Athens Insomnia Scale; HADS-A, Hospital Anxiety and Depression Scale-Anxiety; HADS-D, Hospital Anxiety and Depression Scale-
Depression; MSK, musculoskeletal.
Table 4 Subgroup comparisons on sleep and psychological characteristics between patients with MSK pain and comorbid 
insomnia and patients with MSK pain with no insomnia
MSK pain patients 
with clinical insomnia
(n=120)
MSK pain patients 
with no clinical 
insomnia (n=63)
Mean difference
(95% CI)
Effect size
(Cohen's d) P value*
Anxiety and depression, mean (SD)
  HADS-A (0–21) 7.9 (4.2) 3.9 (2.8) 4.1 (2.9–5.2) 1.12 <0.0001
  HADS-D (0–21) 5.0 (3.6) 1.8 (1.9) 3.2 (2.3–4.2) 1.11 <0.0001
*Statistically significant values are highlighted in bold. Unpaired t-tests were used to determine p values.
HADS-A, Hospital Anxiety and Depression Scale-Anxiety; HADS-D, Hospital Anxiety and Depression Scale-Depression; 
MSK, musculoskeletal. 
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However, until now there has been a complete dearth 
of knowledge on the coexistence and associations in 
patients from general practice, with this study being the 
first to document the prevalence and coexistence of all 
three parameters.
The patients with MSK  in our study scored 9.1 on the 
AIS-8, suggesting they suffer from quite severe insomnia, 
as this is notably worse compared with patients with rheu-
matoid arthritis (a disease with predominantly muscu-
loskeletal manifestations), who report a mean score of 
6.8.23 This underscores the magnitude of insomnia in this 
population from general practice and may be due to the 
high severity of pain complaints in our sample.
A longitudinal study in five UK general practices 
found a prevalence of insomnia of 37%, which is compa-
rable to the current study (40% in those without MSK 
pain). Further, they demonstrated that insomnia was 
associated with pre-existing pain, anxiety and depres-
sion, and insomnia was a risk factor for the subsequent 
onset of anxiety, depression and pain.24 This under-
pins the complex bidirectional relationship between 
the factors, and the need to both consider insomnia in 
those presenting with pain and also pain problems in 
those presenting to the GP for insomnia. This is particu-
larly important as not all of our sample reported having 
consulted the GP specifically for the MSK pain complaint.
With nearly 80% of those with WSP meeting the 
threshold for insomnia, our findings are consistent with 
previous studies showing that insomnia is more prev-
alent in patients with pain in more than one region of 
the body.25 Patients with WSP similarly have more severe 
symptoms of depression and anxiety compared with 
patients with localised pain.26 Similarly, in our sample, 
we documented significantly higher levels of depression 
among patients with WSP.
explanation of findings; the causal link between pain, anxiety, 
depression and sleep
There is a growing body of research suggesting possible 
common pathophysiological and behavioural mecha-
nisms between chronic pain, depressive/mood disorders 
and insomnia.7 27 One explanation is the stress response 
system as it plays a key role in the relationship between 
insomnia and affective disorders in patients with MSK 
pain.10 Tissue injuries may lead to the downregulation of 
the serotonergic pathway, as well as the release and upreg-
ulation of key chemical mediators such as proinflamma-
tory cytokines that may lead to the onset of depression 
and insomnia.27 Sleep deprivation has also been linked 
to increased pain perception and hyperalgesia28 and 
altered ability to modulate pain,29 which may explain why 
insomnia could lead to the development or prognosis of 
chronic pain. Furthermore, the physiological and psycho-
logical consequences of sleep problems could impact an 
individual's ability to cope with pain particularly as sleep 
efficiency has been related to activity limitations and 
health-related quality of life in adolescents with chronic 
pain.30 It is likely that there is a complex cyclical relation-
ship between the three, which could be addressed during 
treatment to enable improved patient care.
Implications for general practice and research
While determining causality is difficult, research consis-
tently indicates that insomnia may both be a risk factor 
for the onset of pain and contribute to the development 
of chronic pain,7 highlighting the importance of sleep. 
Comorbid complaints may increase the risk of poor 
prognosis8 and improvements in depression (eg, antide-
pressants or psychotherapy interventions),31 anxiety and 
sleep32 (eg, by cognitive behavioural therapy) have all 
been associated with improvements in pain, highlighting 
the need for including these aspects during the clinical 
consultation. While sleep disorders may be an indepen-
dent risk factor for onset of pain, they also represent an 
important modifiable factor. For example, in adolescents 
with chronic pain, greater number of minutes awake 
following sleep onset is associated with higher pain the 
following day.33 In general practice, it is useful to know 
which treatment targets are likely to lead to improvements 
in a patient's symptoms. GPs should be aware of the high 
prevalence of comorbid psychological symptoms found 
in this cohort of patients from general practice, particu-
larly considering the association between improvements 
Table 5 Subgroup comparisons on sleep and psychological characteristics between patients with localised MSK pain and 
WSP
Localised MSK 
pain (n=124)
WSP
(n=59)
Difference*
(95% CI)
Effect size
(Cohen's d) P value†
Insomnia (AIS-8 score ≥6), n (%) 74 (59.7) 46 (78.0) 18.3 (3.7 to 30.7) N/A 0.015
Anxiety and depression, mean (SD)
  HADS-A (0–21) 6.4 (4.2) 6.9 (4.4) 0.6 (−0.7 to 1.9) 0.12 0.373
  HADS-D (0–21) 3.5 (3.3) 4.7 (3.8) 1.2 (0.1 to 2.3) 0.34 0.028
*Indicates difference in proportions with 95% CI for AIS-8 and mean difference with 95% CI for HADS. 
†Statistically significant values are highlighted in bold. All p values for HADS were determined by unpaired t-tests, whereas the p value for 
AIS-8 was determined by χ2 test.
AIS-8, Athens Insomnia Scale; HADS-A, Hospital Anxiety and Depression Scale-Anxiety; HADS-D, Hospital Anxiety and Depression 
ScaleDepression; MSK, musculoskeletal; WSP, widespread pain.
copyright.
 on O
ctober 14, 2019 at A
alborg U
niversity Library. P
rotected by
http://bm
jopen.bm
j.com
/
B
M
J O
pen: first published as 10.1136/bm
jopen-2019-031971 on 29 June 2019. D
ow
nloaded from
 
7Sørensen L, et al. BMJ Open 2019;9:e031971. doi:10.1136/bmjopen-2019-031971
Open access
in psychological problems/insomnia and improvements 
in pain.31 32
Although robust evidence to demonstrate effective-
ness of treatments for these comorbid conditions is still 
needed to confidently recommend screening, this study 
reiterates the need for a GP to be aware that among 
primary care attendees consulting for MSK pain, many 
are likely to present with coexisting mood and sleep 
disturbance symptoms. Furthermore, with the view to 
recognise unidentified MSK pain, a GP may choose to 
explore the presence of associated MSK pain in patients 
presenting with insomnia.
strengths and limitations
The study was rigorously designed using predefined 
hypotheses, methods and outcomes that were pilot tested 
to ensure comprehensibility. We used previously vali-
dated and reliable questionnaires to assess insomnia and 
psychological symptoms.
The limitation of the study is the cross-sectional 
study design, meaning we cannot make any inferences 
regarding causality between the parameters assessed. 
Despite having no data on non-respondents, or 
non-completed responses, the threat of selection bias 
is low due to potential participants not being aware of 
the content of the questionnaire. Further longitudinal 
research is needed to outline the mechanisms, which 
link the three parameters. The self-report nature of the 
study could lead to an overestimation of some of the 
problems, for example, the number of patients with 
clinical anxiety or the number of patients using pain-re-
lieving drugs.
Future directions
With increasing global healthcare costs resulting from 
the comorbidity of these four health conditions (MSK 
pain, anxiety, depression and insomnia), there is the 
need to define to further understand how we concep-
tualise and treat these symptoms in general practice. 
Cognitive behavioural therapy targeted at improving 
sleep has been effective in reducing sleep disturbances 
and has a positive effect on pain in older adults with 
osteoarthritis.32 This research could be extended to 
patients with MSK pain in general practice to deter-
mine if this can also positively influence psycholog-
ical symptoms which commonly occur in conjunction 
with comorbid insomnia and pain problems. Further, 
we need to understand the development of MSK pain 
and coexisting psychological symptoms to understand if 
there are critical time-points in which GPs can positively 
affect this trajectory.
COnClusIOn
One in two patients from general practice report 
MSK pain which interferes with activities of daily 
living. The patients with MSK pain more commonly 
suffered from insomnia and had depressive and anxiety 
symptoms. Patients who suffered from both MSK pain 
and insomnia experienced depressive symptoms and 
anxiety far more than patients only suffering from pain. 
Insomnia and affective disorders might be potentially 
modifiable factors to target as part of the treatment for 
MSK pain in general practice.
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